Contact us

News archive 

Jan032018

Best wishes from PX'Therapeutics

Dec202017

Toleranzia AB signs agreement with PX’Therapeutics for large scale manufacturing of TOL2

Dec122017

PX’THERAPEUTICS ANNOUNCES THE SUCCESSFUL COMPLETION OF RGP41 GMP MANUFACTURING FOR MYMETICS

Dec202017

Bioproduction workshop – Polepharma

Dec112017

First Immunotherapies for Infectious Diseases Congress

Oct052016

PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement

Sep082016

PX’Therapeutics to collaborate with Grenoble Hospital and INSERM for the development of a new diagnostic tool to prevent cardiovascular diseases

Jan202016

PX’Therapeutics and Intervacc to collaborate for the development of Strangvac®

May192014

PX’Therapeutics announces the signature of an agreement with Effimune for the development and production of therapeutic antibodies

Jun112013

PX'Therapeutics Announces Appointment of Eric Rougemond as the New CEO

Oct012012

Aguettant, and PX’Therapeutics join forces to boost their activities.

Mar132012

PX’Therapeutics announces EuroNeut-41 Prophylactic HIV Vaccine clinical trial.

Dec212010

PX’Therapeutics to open a new GMP cell culture production facility

May282009

PX’Therapeutics to provide Mymetics Corporation (USA/Switzerland) specific know-how for the production of a recombinant protein key in a novel preventive vaccine against HIV/AIDS.

Oct202008

PX’Therapeutics and Alizé Pharma to collaborate on the development of a recombinant Lasparaginase.

Sep292008

Protein’eXpert Changes Its Name to PX’Therapeutics

Jul072008

Protein’Expert signs agreement with Althea Technologies to expand development and manufacturing services

Jul052007

Creation of PX'Monoclonals